GlassScriptPhysician profile
Adel Catherine Ponder
NPI 1346865672
$1,639.10
in general payments reported to CMS, 2019-2025
13 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $249 · 2023: $890 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $337.43 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $140.25 | 2025 | Spravato |
| Imperative Care, INC | $133.74 | 2025 | Zoom 88-T Large Distal Platform |
| Xeris Pharmaceuticals, INC. | $124.99 | 2023 | Gvoke Hypopen |
| Abbvie INC. | $124.99 | 2023 | |
| Alkermes, INC. | $123.68 | 2025 | Vivitrol |
| Otsuka America Pharmaceutical, INC. | $120.99 | 2023 | Rexulti |
| Inspire Medical Systems, INC. | $104.86 | 2023 | Inspire |
| Bioxcel Therapeutics, INC. | $104.64 | 2023 | Igalmi |
| Axsome Therapeutics, INC. | $103.27 | 2025 | Auvelity |
| Regeneron Healthcare Solutions, INC. | $99.63 | 2023 | Dupixent |
| Neurelis, INC. | $84.76 | 2023 | Valtoco |
| Alnylam Pharmaceuticals INC. | $35.87 | 2023 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adel Ponder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.